December 2016
-
Many of the attendees at the upcoming RDD meeting in Puerto Rico who stop by Team Consulting’s table to check out the company’s Occoris inhaler probably won’t realize that the Team staff with whom they… Read more . . .
-
Copley Scientific will launch several new cascade impactor accessories designed to meet requirements for testing of fluticasone propionate inhalation powder set out in a new USP monograph at RDD 2014, the company has said. The… Read more . . .
-
Submit abstracts for posters and podium presentations by August 15, 2014 at woolcock.org.au/isam2014abstracts/ Abstracts accpted for the conference will be published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery. Read more . . .
-
According to Hovione, the United States Patent and Trademark Office (USPTO) has granted the company a patent for its XCAPs capsule-based dry powder inhaler. The European Patent Office granted the company a patent for the… Read more . . .
-
The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for MannKind’s Afrezza inhaled insulin by three months, according to MannKind. The original date was April 15, 2014; the new date is July… Read more . . .
-
On April 2, 2014, the FDA issued a draft guidance for fentanyl citrate nasal spray. The guidance offers an in vitro option, saying, “If the test product is qualitatively (Q1) and quantitatively (Q2) the same… Read more . . .
-
Swedish pharmaceutical company Meda has confirmed that Mylan approached the company with a takeover offer and that Meda rejected the offer. According to Meda, “All continued discussions between Meda and Mylan have been terminated without… Read more . . .
-
Swedish CDMO Recipharm, which has a dedicated DPI manufacturing facility in the UK, has begun trading on the Stockholm stock exchange, according to NASDAQ OMX. Recipharm had announced the IPO in March 2014. Recipharm CEO… Read more . . .
-
In anticipation of the potential commercialization of its Arikayce inhaled liposomal amikacin, Insmed has announced a number of management changes designed to “better align the organization with the company’s growth opportunities.” Those changes are: Renu… Read more . . .
-
The FDA has announced a funding opportunity for a research project titled “Development of Clinically Relevant In Vitro Performance Test for Generic OIDPs: Physiologically Relevant Models for Aerodynamic Particle Size Distribution Analysis.” Two grants of… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland